E
Talphera, Inc. TLPH
$0.50 $0.00961.96%
Recommendation
Sell
Prev Close
$0.4904
Volume
12,345
Avg Vol (90D)
80,158
Market Cap
$8.39M
Dividend & Yield
--
52-Week Range
$0.45 - $1.27
P/E (TTM)
--
EPS (TTM)
-$0.5052
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?
4/4/2025 - Zacks Investment Research
Talphera, Inc. Earnings Call: Progress Amid Challenges
4/2/2025 - TipRanks Financial Blog
Talphera, Inc. (NASDAQ:TLPH) Short Interest Update
4/1/2025 - Ticker Report
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights
4/1/2025 - GuruFocus
Q4 2024 Talphera Inc Earnings Call Transcript
4/1/2025 - GuruFocus
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
3/31/2025 - SeekingAlpha.com: All News
Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
3/31/2025 - SeekingAlpha
Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
3/31/2025 - Seeking Alpha: Transcripts
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/31/2025 - GuruFocus
Talphera reports Q4 EPS (7c) vs. (25c) last year
3/31/2025 - TipRanks Financial Blog
Talphera reports Q4 EPS (7c) vs. (25c) last year
3/31/2025 - The Fly
Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/31/2025 - PR Newswire
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients ...
3/31/2025 - GuruFocus
Talphera announces agreement with FDA to reduce NEPHRO CRRT study size
3/31/2025 - The Fly
Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
3/31/2025 - PR Newswire
Earnings Outlook For Talphera
3/28/2025 - Benzinga
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call ...
3/26/2025 - GuruFocus
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
3/26/2025 - PR Newswire
Talphera (NASDAQ:TLPH) Upgraded at RODMAN&RENSHAW
1/31/2025 - Ticker Report
Talphera (NASDAQ:TLPH) Now Covered by Analysts at Rodman & Renshaw
1/30/2025 - Ticker Report
Talphera initiated with a Buy at Rodman & Renshaw
1/28/2025 - TipRanks Financial Blog
Talphera initiated with bullish view at Rodman & Renshaw
1/28/2025 - The Fly
HC Wainwright Reiterates Buy Rating for Talphera (NASDAQ:TLPH)
1/22/2025 - Ticker Report
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the ...
1/14/2025 - GuruFocus
Talphera reaches agreement with FDA in Nephro CRRT study
1/14/2025 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$15.16M
EBIT (TTM)
-$15.25M
Net Income (TTM)
-$13.00M
Balance Sheet
Total Assets (Q)
$18.24M
Total Debt (Q)
$6.53M
Total Liabilities (Q)
$10.24M
Book Value Per Share (Q)
$0.4698
Cash Flow
Cash from Operations (TTM)
-$12.68M
Cash from Investing (TTM)
$3.78M
Cash from Financing (TTM)
$12.04M
Net Change in Cash (TTM)
$3.14M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.49
7-Day Total Return
-14.24%
30-Day Total Return
-10.63%
60-Day Total Return
-13.87%
90-Day Total Return
-29.28%
Year to Date Total Return
-15.27%
1-Year Total Return
-56.14%
2-Year Total Return
-24.81%
3-Year Total Return
-90.67%
5-Year Total Return
-98.09%
52-week Low
Mar 31, 2025 - $0.45
52-week High
May 15, 2024 - $1.27
Valuation
Market Cap
$8.39M - Nano Cap
Enterprise Value
$6.05M
Price/Sales (TTM)
--
Price/Book (Q)
1.04
Dividends and Shares
Shares Outstanding
26.24M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
talphera.com
Phone Number
650 216 3500
Address
1850 Gateway Drive
San Mateo, CA 94404
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a... more
NASDAQ 04/11/2025 3:59PM Eastern Quotes delayed
Weiss Ratings